Abstract: The invention relates to biodegradable, metal alloy-containing compositions, methods for their preparation and applications for their use. The compositions include magnesium and other components, such as yttrium, calcium, silver, cerium, and zirconium; or zinc, silver, cerium, and zirconium; or aluminum, zinc, calcium, manganese, silver, yttrium; or strontium, calcium, zinc. The compositions are prepared by vacuum induction/crucible melting together the components and casting the melted mixture in a preheated mild steel/copper mold. In certain embodiments, the compositions of the invention are particularly useful for forming medical devices for implantation into a body of a patient.

Abstract: A sol-gel bioactive glass precursor, method for making sol-gel glasses, resultant sol-gel bioactive glasses, and methods of use thereof which include introducing Na2O into the glass network during the sol-gel process through the use of Na-ethoxide, NaCl, or sodium silicate rather than sodium nitrate. Medical and industrial uses of such glasses.

Abstract: Disclosed is a quickly soluble oral film dosage for masking a nasty taste, in particular, a quickly soluble oral film dosage comprising a stevioside based sweetener and a high potency sweetener in a ratio by weight (w/w) of 1:3 to 3:1, which may efficiently mask a bitter or nasty taste of a medicine and may be quickly dissolved in a mouth without water, thereby improving an aftertaste thereof thus enhancing dosage acceptability of a patient.

Abstract: The present invention relates to a method of controlling weeds using mixtures of HPPD inhibiting herbicides and plant growth regulators. It also relates to mixtures of HPPD inhibiting herbicides and plant growth regulators per se, and compositions comprising the same.

Abstract: Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided.

Abstract: The present invention relates, inter alia, to a novel herbicide formulation comprising:— (a) an aqueous phase; (b) an HPPD inhibitor in suspension in the aqueous phase; (c) an encapsulated chloroacetamide or an isoxazoline herbicide in suspension in the aqueous phase; (d) glyphosate and/or glufosinate or an agrochemically acceptable salt thereof, in solution in the aqueous phase. The invention further relates to a process for the preparation of an herbicide formulation of the invention and to a process for the control of unwanted vegetation.

Abstract: A rapidly dispersing dosage form is described. The dosage form releases its active ingredients within a period of less than about ninety seconds. These dosage forms exhibit a three-dimensional shape that is retained for adequate storage but is readily dispersed in the presence of excess moisture. Also disclosed are methods of administration of a medicament and a process for the preparation of rapidly dispersing dosage forms.

Abstract: The present invention relates to a method of selectively controlling weeds at a locus comprising crop plants and weeds, wherein the method comprises application to the locus of a weed controlling amount of an aqueous spray composition comprising a compound of formula (I) wherein R1 is selected from the group consisting of C1-C6alkyl, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C3-C6cycloalkyl, C1-C6haloalkyl, C1-C4alkoxy-C1-C4alkyl and C1-C4alkoxy- C1-C4alkoxy-C1-C4alkyl; and R2 is C1-C6haloalkyl; or an agriculturally acceptable salt therefore; wherein in the pH of the spray composition is from about 5 to about 9. The invention further relates to a liquid substantially non-aqueous herbicide composition comprising a compound of formula (I) as defined above and a pH adjuster, and to the use of a pH adjuster to reduce the phytotoxicity of a compound of formula (I) in crop plants.

Abstract: Medical devices that are resistant to biofilm development and methods of the manufacture of biofilm resistant medical devices are provided. One or more bacteriophages are tethered to the surface of a medical device or a hydrogei-type coating on the surface of the device by covalent bonding while maintaining bacteriophage infective or lytic activity. The presence of the bacteriophages on a medical device, such as an indwelling medical device, prevents biofilm formation or reduces existing biofilm formation on the surface of the device when in use. These devices address the long felt need for biofilm resistant devices that increase safety and reduce complications normally associated with prior indwelling or other medical devices.

Abstract: Embodiments of the present invention encompass fascia, fat, and dermis fibrous compositions, and methods for their manufacture and use. In a first aspect, embodiments of the present invention encompass methods for obtaining a fascia fiber for use in producing a biotextile. Exemplary methods may include treating a cadaveric fascia tissue with acetone, and obtaining the fascia fibers from the treated fascia tissue. In some cases, methods may include processing the fascia fibers to produce the fibrous fascia biotextile.

Abstract: An aqueous suspension concentrate (SC) composition of a crop protection active compound is provided, the concentrate comprising: (a) 50 to 700 g/l of an active ingredient comprising at least one compound active in crop protection; and (b) a concentrate stabilizing component consisting of: (i) up to 150 g/l of at least one non-ionic dispersing agent; and/or (ii) to 150 g/l of at least one anionic dispersing agent; and 10 (c) 200 to 800 g/l of water; with the proviso that in the case that the suspension concentrate comprises an active ingredient other than an azole and the concentrate stabilizing component consists of an anionic dispersing agent only, the anionic dispersing agent is present in an amount of greater than 30 g/l; or in the case that the suspension concentrate comprises an azole derivative as the active ingredient and the concentrate stabilizing component consists of both an anionic dispersing agent and a non-ionic dispersing agent, the anionic dispersing agent is present in an amount of greater th

Abstract: The present invention generally relates to a glyphosate formulation with enhanced viscosity, said formulation containing a thickening composition comprising at least one nitrogen-containing surfactant.

Abstract: The instant invention relates to compositions and methods for the control of nematodes and soil borne diseases using compositions comprising high terpene containing oils and one or more surfactants and alcohol. The invention also relates to methods for conditioning soil to improve overall plant health and growth by among others increasing the wetted soil volume available for water utilization by plant roots using the disclosed compositions.

Abstract: Macroporous 3-D tissue engineering scaffold are manufactured by contacting an article comprising multiple distinct macroparticulate porogens distributed within a polymer scaffold, wherein the porogens are selectively and sequentially dissolvable by corresponding biocompatible stimuli.

Abstract: A liquid herbicidal composition containing pinoxaden and an adjuvant, where the adjuvant is a built-in adjuvant consisting of a trisester of phosphoric acid with aliphatic or aromatic alcohols and/or a bis-ester of alkyl phosphonic acids with aliphatic or aromatic alcohols.

Abstract: Disclosed is a topical skin care composition, and method for its use, that includes 55 to 65% by weight of water, 15 to 20% by weight of a combination of 3,3,5-Trimethylcyclohexyl 2-hydroxybenzoate (homosalate), 1-(4-Methoxyphenyl)-3-(4-tert-butylphenyl)propane-1,3-dione (avobenzone), 2-ethylhexyl 2-hydroxybenzoate (octisalate), and 2-ethylhexyl 2-cyano-3,3-diphenyl-2-propenoate (octocrylene), 3 to 4% by weight of distearlydimonium chloride, and 1 to 3% by weight of a combination of euterpe oleracea fruit extract, punica granatum sterols, caprooyl tetrapeptide-3, tocopherol or tocopherol acetate, and niacinamide, wherein the composition has a sun protection factor of at least 15 or about 15 to 20.

Abstract: A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3?-methoxy-pregna-5-ene-20-one (3?-methoxy-PREG).

Abstract: A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising: step A) obtaining an adhesive agent layer composition comprising free ropinirole in an amount which results in a content of 5 to 13.2% by mass in an obtained adhesive agent layer; step B) heating the adhesive agent layer composition at a temperature in a range from 50 to 76° C. for 5 minutes to 24 hours; and step C) cooling the heated adhesive agent layer composition to normal temperature at an average rate of temperature drop of 1 to 20° C./hour, thereby obtaining the adhesive agent layer comprising the free ropinirole at a supersaturated concentration in a dissolved form.

Abstract: Microencapsulated formulations of macrolide lactones (abamectin, milbemectin, milbemycins emamectin, avermectins, ivermectins) wherein the active ingredient is protected from UV-degradation, with exceptional release characteristics resembling those of an emulsion concentrate or, if desired, of long-lasting effect; further with appropriate rheological properties, and with reduced toxicity. The invention provides a unique microencapsulation process for the chemical stability and biological activity of mectins, e.g. abamectin, and provides microcapsules of mectins to be used in formulations CS, WG/CS, ZC, EC/CS and any formulation type containing microcapsules and combination with other biologically active ingredients.

Abstract: Microencapsulated formulations of macrolide lactones (abamectin, milbemectin, milbemycins emamectin, avermectins, ivermectins) wherein the active ingredient is protected from UV-degradation, with exceptional release characteristics resembling those of an emulsion concentrate or, if desired, of long-lasting effect; further with appropriate rheological properties, and with reduced toxicity. The invention provides a unique microencapsulation process for the chemical stability and biological activity of mectins, e.g. abamectin, and provides microcapsules of mectins to be used in formulations CS, WG/CS, ZC, EC/CS and any formulation type containing microcapsules and combination with other biologically active ingredients.